Instruction manual

Contents

| 1. Intended Use | 1 |
|---|-----|
| 2. Clinical Applications and Principle of the Assay | 1 |
| 3. Kit Contents | 2 |
| 4. Storage and Shelf Life | 2 |
| 5. Precautions of Use | 3 |
| 6. Sample Collection, Handling and Storage | 3 |
| 7. Assay Procedure | 4 |
| 8. Quantitative and Qualitative Interpretation | 5 |
| 9. Technical Data | 6 |
| 10. Performance Data | 6-7 |
| 11. Literature | 7 |
| A : Pipetting scheme | 8 |
| B : Test Procedure | 9 |

1. Intended Use

AESKULISA Phospholipid-8S-A is a solid phase enzyme immunoassay for the separate qualitative and quantitative detection of IgA antibodies against phospholipids in human serum. Each well is coated with highly purified bovine cardiolipin, ß2-glycoprotein I, phosphatidyl- serine, -inositol, ethanolamine, -choline and sphingomyelin.

The assay is an aid in the diagnosis and risk estimation of thrombosis in patients with systemic lupus erythematosus and antiphospholipid syndrome (APS).

2. Clinical Application and Principle of the Assay

Antibodies against phospholipids, components of the biological membranes, are specific for phospholipids such as cardiolipin, phosphatidyl -inositol, -ethanolamine, -choline, sphingomyelin and phosphatidic acid.

Anti-phospholipid antibodies are frequently found in sera of patients with systemic lupus erythematosus (SLE) and related diseases. The occurrence of anti-phospholipid antibodies in patients with SLE and related diseases is typical for a secondary anti-phospholipid syndrome (APS). In contrast, anti-phospholipid antibodies in patients with no other autoimmune diseases characterize the primary APS.

Many studies have shown a correlation beTween 20 these autoantibodies and an enhanced incidence of thrombosis, thrombocytopenia and habitual abortions (as a consequence of placental infarct). The exact mechanisms by which pathogenic anti-phospholipid antibodies induce thrombosis is not yet revealed fully.

Principle of the test

Serum samples diluted 1:101 are incubated in the microplates coated with the specific antigen. Patient's antibodies, if present in the specimen, bind to the antigen. The unbound fraction is washed off in the following step. Afterwards anti-human immunoglobulins conjugated to horseradish peroxidase (conjugate) are incubated and react with the antigen-antibody complex of the samples in the microplates. Unbound conjugate is washed off in the following step. Addition of TMB-substrate generates an enzymatic colorimetric (blue) reaction, which is stopped by diluted acid (color changes to yellow). The rate of color formation from the chromogen is a function of the amount of conjugate bound to the antigen-antibody complex and this is proportional to the initial concentration of the respective antibodies in the patient sample.

3. Kit Contents

To be reconstituted:

5x Sample Buffer 1 vial, 20 ml - 5x concentrated (capped white: yellow solution)

Containing: Tris, NaCl, BSA, sodium azide < 0.1% (preservative)

50x Wash Buffer 1 vial, 20 ml - 50x concentrated (capped white: green solution)

Containing: Tris, NaCl, Tween 20, sodium azide < 0.1% (preservative)

Ready to use:

Negative Control 1 vial, 1.5 ml (capped green: colorless solution)

Containing: Human serum (diluted), sodium azide < 0.1% (preservative)

Positive Control 1 vial, 1.5 ml (capped red: yellow solution)

Containing: Human serum (diluted), sodium azide < 0.1% (preservative)

Cut-off Calibrator 1 vial, 1.5 ml (capped blue: yellow solution)

Containing: Human serum (diluted), sodium azide < 0.1% (preservative)

Calibrators 6 vials, 1.5 ml each 0, 3, 10, 30, 100, 300 U/ml

(color increasing with concentration: yellow solutions)

Containing: Human serum (diluted), sodium azide < 0.1% (preservative)

Conjugate 1 vial, 15 ml IgA (capped red: red solution)

Containing: Anti-human immunoglobulins conjugated to horseradish peroxidase

TMB Substrate 1 vial, 15 ml (capped black)

Containing: Stabilized TMB/H2O2

Stop Solution 1 vial, 15 ml (capped white: colorless solution)

Containing: 1M Hydrochloric Acid

Microtiterplate 12x 8 well strips with breakaway microwells

Coating see paragraph 1

Material required but not provided:

Microtiter plate reader 450 nm reading filter and optional 620 nm reference filter (600-690 nm). Glass ware(cylinder 100-1000ml), test tubes for dilutions. Vortex mixer, precision pipettes (10, 100, 200, 500, 1000 μ l) or adjustable multipipette (100-1000ml). Microplate washing device (300 μ l repeating or multichannel pipette or automated system), adsorbent paper.

Our tests are designed to be used with purified water according to the definition of the United States Pharmacopeia (USP 26 - NF 21) and the European Pharmacopeia (Eur.Ph. 4th ed.).

4. Storage and Shelf Life

Store all reagents and the microplate at 2-8°C/35-46°F, in their original containers. Once prepared, reconstituted solutions are stable for 1 month at 4°C/39°F, at least. **Reagents and the microplate** shall be used within the expiry date indicated on each component, only. Avoid intense exposure of TMB solution to light. Store microplates in designated foil, including the desiccant, and seal tightly.

5. Precautions of Use

5.1 Health hazard data

This product is for **IN VITRO DIAGNOSTIC USE** only. Thus, only staff trained and specially advised in methods of in vitro diagnostics may perform the kit. Although this product is not considered particularly toxic or dangerous in conditions of normal use, refer to the following for maximum safety:

Recommendations and precautions

This kit contains potentially hazardous components. Though kit reagents are not classified being irritant to eyes and skin we recommend to avoid contact with eyes and skin and wear disposable gloves.

WARNING! Calibrators, Controls and Buffers contain sodium azide (NaN₃) as a preservative. NaN₃ may be toxic if ingested or adsorbed by skin or eyes. NaN₃ may react with lead and copper plumbing to form highly explosive metal azides. On disposal, flush with a large volume of water to prevent azide build-up. Please refer to decontamination procedures as outlined by CDC or other local/national guidelines.

Do not smoke, eat or drink when manipulating the kit.

Do not pipette by mouth.

All human source material used for some reagents of this kit (controls, standards e.g.) has been tested by approved methods and found negative for HbsAg, Hepatitis C and HIV 1. However, no test can guarantee the absence of viral agents in such material completely. Thus handle kit controls, standards and patient samples as if capable of transmitting infectious diseases and according to national requirements.

5.2 General directions for use

Do not mix or substitute reagents or microplates from different lot numbers. This may lead to variations in the results.

Allow all components to reach room temperature (20-32°C/68-89.6°F) before use, mix well and follow the recommended incubation scheme for an optimum performance of the test.

Incubation: We recommend test performance at 30°C/86°F for automated systems.

Never expose components to higher temperature than 37°C/98.6 °F.

Always pipette substrate solution with brand new tips only. Protect this reagent from light. Never pipette conjugate with tips used with other reagents prior.

A definite clinical diagnosis should not be based on the results of the performed test only, but should be made by the physician after all clinical and laboratory findings have been evaluated. The diagnosis is to be verified using different diagnostic methods.

6. Sample Collection, Handling and Storage

Use preferentially freshly collected serum samples. Blood withdrawal must follow national requirements.

Do not use icteric, lipemic, hemolysed or bacterially contaminated samples. Sera with particles should be cleared by low speed centrifugation (<1000 x g). Blood samples should be collected in clean, dry and empty tubes. After separation, the serum samples should be used immediately, respectively stored tightly closed at $2-8^{\circ}\text{C}/35-46^{\circ}\text{F}$ up to three days, or frozen at $-20^{\circ}\text{C}/-4^{\circ}\text{F}$ for longer periods.

7. Assay Procedure

7.1 Preparations prior to pipetting

Dilute concentrated reagents:

Dilute the concentrated sample buffer 1:5 with distilled water (e.g. 20 ml plus 80 ml). Dilute the concentrated wash buffer 1:50 with distilled water (e.g. 20 ml plus 980 ml).

Samples:

Dilute serum samples 1:101 with sample buffer (1x) e.g. 1000 μl sample buffer (1x) + 10 μl serum. Mix well!

Washing:

Prepare 20 ml of diluted wash buffer (1x) per 8 wells or 200 ml for 96 wells e.g. 4 ml concentrate plus 196 ml distilled water.

Automated washing:

Consider excess volumes required for setting up the instrument and dead volume of robot pipette.

Manual washing:

Discard liquid from wells by inverting the plate. Knock the microwell frame with wells downside vigorously on clean adsorbent paper. Pipette 300 µl of diluted wash buffer into each well, wait for 20 seconds. Repeat the whole procedure twice again.

Microplates:

Calculate the number of wells required for the test. Remove unused wells from the frame, replace and store in the provided plastic bag, together with desiccant, seal tightly (2-8°C/35-46°F).

7.2 Work flow

For pipetting scheme see Annex A, for the test procedure see Annex B We recommend pipetting samples and calibrators in duplicate.

Cut-off calibrator should be used for qualitative testing only.

- Pipette 100 μl of each patient's diluted serum into the designated microwells.
- Pipette 100 µl calibrators OR cut-off calibrator and negative and positive controls into the designated wells.
- Incubate for 30 minutes at 20-32°C/68-89.6°F.
- Wash 3x with 300 µl washing buffer (diluted 1:50).
- Pipette 100 µl conjugate into each well.
- Incubate for 30 minutes at 20-32°C/68-89.6°F.
- Wash 3x with 300 µl washing buffer (diluted 1:50).
- Pipette 100 µl TMB substrate into each well.
- Incubate for 30 minutes at 20-32°C/68-89.6°F, protected from intense light.
- Pipette 100 µl stop solution into each well, using the same order as pipetting the substrate.
- Incubate 5 minutes minimum.
- Agitate plate carefully for 5 sec.
- Read absorbance at 450 nm (optionally 450/620 nm) within 30 minutes.

8. Quantitative and Qualitative Interpretation

For quantitative interpretation establish the standard curve by plotting the optical density (OD) of each calibrator (y-axis) with respect to the corresponding concentration values in U/ml (x-axis). For best results we recommend log/lin coordinates and 4-Parameter Fit. From the OD of each sample, read the corresponding antibody concentrations expressed in U/ml.

| Normal Range | Equivocal Range | Positive Results |
|--------------|------------------------|------------------|
| < 12 U/ml | 12 - 18 U/ml | >18 U/ml |

Example of a standard curve

We recommend pipetting calibrators in parallel for each run.

| Calibrators IgA | OD 450/620 nm | CV % (Variation) |
|-----------------|---------------|------------------|
| | | |
| 0 U/ml | 0.056 | 2.5 |
| 3 U/ml | 0.144 | 1.5 |
| 10 U/ml | 0.311 | 2.4 |
| 30 U/ml | 0.623 | 3.2 |
| 100 U/ml | 1.228 | 3.1 |
| 300 U/ml | 2.091 | 0.9 |

Example of calculation

| Patient | Replicate (OD) | Mean (OD) | Result (U/ml) |
|---------|----------------|-----------|---------------|
| | | | |
| P 01 | 0.594/0.598 | 0.596 | 26.6 |
| P 02 | 0.878/0.854 | 0.866 | 49.3 |

For lot specific data, see enclosed quality control leaflet. Medical laboratories might perform an inhouse Quality Control by using own controls and/or internal pooled sera, as foreseen by EU regulations.

Do not use this example for interpreting patients results!

Each laboratory should establish its own normal range based upon its own techniques, controls, equipment and patient population according to their own established procedures.

For qualitative interpretation read the optical density of the cut-off calibrator and the patient samples. Compare patient'sOD with the OD of the cut-off calibrator. For qualitative interpretation we recommend to consider sera within a range of 20% around the cut-off value as equivocal. All samples with higher ODs are considered positive, samples with lower ODs are considered negative.

Negative: OD patient < 0.8 x OD cut-off

Equivocal: $0.8 \times OD_{cut-off} \le OD_{patient} \le 1.2 \times OD_{cut-off}$

Positive OD patient > 1.2 x OD cut-off

9. Technical Data

Sample material: serum

Sample volume: 10 μl of sample diluted 1:101 with 1x sample buffer

Total incubation time: 90 minutes at 20-32°C/68-89.6°F

Calibration range: 0-300 U/ml

Analytical sensitivity: 1.0 U/ml

Storage: at 2-8°C/35-46°F use original vials, only

Number of determinations: 96 tests

10. Performance Data

10.1 Analytical sensitivity

Testing sample buffer 30 times on *AESKULISA Phospholipid-8S* gave an analytical sensivity of 1.0 U/ml.

10.2 Specificity and sensitivity

The microplate is coated with β 2-glycoprotein I, cardiolipin, phophatidylcholine, -ethanolamine, -inositol, -serine and sphingomyelin. No crossreactivities to other autoantigens have been found. Since Phospholipid-8S consists of various antigens, the known values for IgG sensitivity and specificity are listed in the table below.

| | Sensitivity | Specificity |
|-----------------------|-------------|-------------|
| Cardiolipin | 67% | 73% |
| b2Glyco I | 69% | 69% |
| Phosphatidylserine | 62% | 83% |
| Phosphatidyl-Inositol | 69% | 75% |
| Ethanolamine | 62% | 78% |
| Choline | 62% | 79% |

10.3 Linearity

Chosen sera have been tested with this kit and found to dilute linearly. However, due to the heterogeneous nature of human autoantibodies there might be samples that do not follow this rule.

| | | measured | expected | |
|--------|----------|---------------|---------------|----------|
| Sample | Dilution | concentration | concentration | Recovery |
| No. | Factor | (U/ml) | (U/ml) | (%) |
| 1 | 1 / 100 | 226.0 | 224.0 | 100.9 |
| | 1 / 200 | 109.0 | 112.0 | 97.3 |
| | 1 / 400 | 57.0 | 56.0 | 101.8 |
| | 1 / 800 | 26.0 | 28.0 | 92.9 |
| 2 | 1 / 100 | 170.0 | 173.0 | 98.7 |
| | 1 / 200 | 87.0 | 86.5 | 100.6 |
| | 1 / 400 | 41.5 | 43.3 | 95.8 |
| | 1 / 800 | 20.8 | 21.6 | 96.3 |

10.4 Precision

To determine the precision of the assay, the variability (intra and inter-assay) was assessed by examining its reproducibility on three serum samples selected to represent a range over the standard curve.

| In | tra-Assa | ay |
|--------|----------|-----|
| Sample | Mean | CV |
| No. | (U/ml) | (%) |
| 1 | 228.0 | 6.3 |
| 2 | 169.0 | 4.8 |
| 3 | 59.0 | 3.2 |

| In | ter-Assa | ay |
|--------|----------|-----|
| Sample | Mean | CV |
| No. | (U/ml) | (%) |
| 1 | 217.0 | 5.8 |
| 2 | 154.0 | 2.8 |
| 3 | 53.0 | 1.6 |

10.5 Calibration

Due to the lack of international reference calibration this assay is calibrated in arbitrary units (U/ml).

11. Literature

1. Boey, M.L., Colaco, C.B., Gharavi, A.E., et al. (1983):

Thrombosis in systemic lupus erythematosus: striking association with the presence of circulating lupus anticoagulant.

Br. Med. J. 287: 1021-1023.

2. Gastineau, D.A., Kazmier, F.J., Nichols, W.L., Bowie, E.J. (1985):

Lupus anticoagulant: an analysis of the clinical and laboratory features of 219 cases. Am. J. Hematol. 19: 265-267.

3. McNeil HP, Simpson RJ, Chesterman CN, Kirilis SA (1990):

Anti-phospholipid antibodies are directed against a complex antigen that includes a lipid-binding inhibitor of coagulation: ß2-Glycoprotein I (apolipoprotein H).

Proc Natl Acad Sci USA 87: 4120-4124.

- 4. Wöhrle R, Matthias T, von Landenberg P, Oppermann M, Helmke K, Förger F (2000): Clinical relevance of antibodies against different phospholipids.

 Journal of Autoimmunity 15: A60.
- 5. Wöhrle R, Matthias T, von Landenberg P, Oppermann M, Förger F, Helmke K (2000):

A new anti-phospholipid-antibody ELISA - sensitivity and specificity for cerebrovascular insults in autoimmune diseases.

Journal of Autoimmunity Vol 15: A 60.

ANNEX A: Pipetting scheme

We suggest pipetting calibrators, controls and samples as follows:

For quantitative interpretation use calibrators to establish a standard curve.

For qualitative interpretation use cut-off calibrator.

| | - | | | erpreta a stand | | | for qualitative interpretation use cut-off calibrator | | | | | |
|---|------|------|----|--------------------|---|---|--|-----|---|----|----|----|
| | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | 11 | 12 |
| Α | CalA | CalE | P1 | | | | NC | P2 | | | | |
| В | CalA | CalE | P1 | | | | NC | P2 | | | | |
| С | CalB | CalF | P2 | | | | CC | P3 | | | | |
| D | CalB | CalF | P2 | | | | CC | P3 | | | | |
| E | CalC | PC | P3 | | | | PC | | | | | |
| F | CalC | PC | P3 | | | | PC | ••• | | | | |
| G | CalD | NC | | | | | P1 | ••• | | | | |
| Н | CalD | NC | | | | | P1 | | | | | |


CalA: calibrator A, CalB: calibrator B, CalC: calibrator C, CalD: calibrator D, CalE: calibrator E,


002:2007-08-28


CalF: calibrator F
PC: positive control
NC: negative control
CC: Cut-off calibrator

P1: patient 1 P2: patient 2 P3: patient 3

Annex B: Test Procedure







| Assay/Test: | | | ll l | Incubation / I | / Inkub. : | | mim_ | | Date/ | Date/ Datum: | | |
|--------------|-------------------------|-----|----------------|----------------|------------|----|------|---|--------------------------|--------------|----|----|
| [emperatur | [emperature/Temperatur: | ur: | Н _о |)° | | 2. | mim | į | į | • | | |
| Vame: | | | | | | 3. | mim_ | S | Signature/Unterschrift:. | nterschrift: | | |
| | 1 | 2 | ω | 4 | \$ | 9 | 7 | ∞ | 6 | 10 | 11 | 12 |
| \mathbf{A} | | | | | | | | | | | | |
| В | | | | | | | | | | | | |
| C | | | | | | | | | | | | |
| D | | | | | | | | | | | | |
| E | | | | | | | | | | | | |
| F | | | | | | | | | | | | |
| G | | | | | | | | | | | | |
| Н | | | | | | | | | | | | |
| | | | | | | | | | | | | |

AESKU.DIAGNOSTICS GmbH 55234 Wendelsheim - Mikroforum Ring 2, Germany Phone: + 49-6734-96270, Fax: + 49-6734-962727

| | Diagnosi in vitro | ♦ For in vitro diagnostic use |
|-------------------|---|---|
| ן איז ו | ◆ Pour diagnostic in vitro | ◆ Para uso diagnóstico in vitro |
| 140 | ◆ In Vitro Diagnostikum◆ Para uso Diagnóstico in vitro | ♦ In Vitro Διαγνωστικό μέσο |
| | · | A Catalaga numbar |
| 555 | Numero d'ordine Référence Cataloque | ◆ Cataloge number◆ Numéro de catálogo |
| REF | Bestellnummer | ◆ Αριθμός παραγγελίας |
| | Número de catálogo | 7 740.0403 114441101143 |
| | Descrizione lotto | ♦ Lot |
| LOT | ♦ Lot | ♦ Lote |
| LOI | ♦ Chargen Bezeichnung | Χαρακτηρισμός παρτίδας |
| | ◆ Lote | |
| | ◆ Conformità europea | ◆ EC Declaration of Conformity |
| (€ | ◆ Déclaration CE de Conformité | Declaración CE de Conformidad |
| • | ◆ Europäische Konformität | ◆ Ευρωπαϊκή συμφωνία |
| | ◆ Déclaração CE de Conformidade | |
| \os / | 96 determinazioni | ♦ 96 tests |
| 90/ | ◆ 96 tests◆ 96 Bestimmungen | ◆ 96 pruebas◆ 96 προσδιορισμοί |
| V | ♦ 96 Testes | ▼ 30 προσσίορισμοί |
| | Rispettare le istruzioni per l'uso | ♦ See instructions for use |
| \longrightarrow | ◆ Voir les instructions d'utilisation | ◆ Ver las instrucciones de uso |
| 1 | Gebrauchsanweisung beachten | Λάβετε υπόψη τις οδηγίες χρήσης |
| 1 | ♦ Ver as instrucões de uso | |
| | ◆ Da utilizzarsi entro | ◆ Use by |
| \ <u>\</u> | ◆ Utilise avant le | ◆ Utilizar antes de |
| | ♦ Verwendbar bis | Χρήση μέχρι |
| | Utilizar antes de | |
| ∩ ,—+8°C | ♦ Conservare a 2-8°C | ◆ Store at 2-8°C (35-46°F) |
| 12C_M | ♦ Conserver à 2-8°C | ◆ Conservar a 2-8°C |
| | ◆ Lagerung bei 2-8°C | Φυλάσσεται στους 2-8°C |
| | ♦ Conservar entre 2-8°C | A Manufachus-Jerr |
| | ◆ Prodotto da◆ Fabriqué par | ◆ Manufactured by◆ Fabricado por |
| | → Hergestellt von | Κατασκευάζεται από |
| | Fabricado por | ▼ Naraokeoagerarano |
| | Calibratore cut-off | ◆ Cut off Calibrator |
| 00 041 | Etalon Seuil | Calibrador de cut-off |
| CO-CAL | ♦ Grenzwert Kalibrator | Οριακός ορός Αντιδραστήριο βαθμονόμησης |
| | ♦ Calibrador de cut-off | |
| | ◆ Controllo positivo | ◆ Positive Control |
| CON + | ◆ Contrôle Positif | ◆ Control Positivo |
| 0014 | Positiv Kontrolle | Θετικός ορός ελέγχου |
| | ◆ Controlo positivo | |
| | ◆ Controllo negativo | Negative Control |
| CON - | ◆ Contrôle Négatif | ◆ Control Negativo |
| 0011 | Negativ KontrolleControlo negativo | Αρνητικός ορός ελέγχου |
| | ◆ Calibratore | ◆ Calibrator |
| | ♦ Etalon | ◆ Calibrator |
| CAL | ♦ Kalibrator | Αντιδραστήριο βαθμονόμησης |
| | ◆ Calibrador | |
| | ♦ Recupero | ♦ Recovery |
| RC | ◆ Corrélation | ♦ Recuperado |
| 1.0 | ♦ Wiederfindung | ♦ Ανάκτηση |
| | ♦ Recuperacão | |
| | ♦ Conjugato | ◆ Conjugate |
| CONJ | ◆ Conjugé ▲ Konjugat | ♦ Conjugado |
| 23,10 | ◆ Konjugat◆ Conjugado | Σύζευγμα |
| | Micropiastra rivestita | ◆ Coated microtiter plate |
| NAD. | Microplague sensibilisée | Microplaca sensibilizada |
| MP | Beschichtete Mikrotiterplatte | ◆ Επικαλυμμένη μικροπλάκα |
| | ♦ Microplaca revestida | |
| | Piastra ad aghi rivestita | ◆ Coated pinplate |
| DIME | ♦ Pinplate sensibilisée | ♦ Pinplate sensibilizada |
| PINP | ◆ Beschichtete Pinplatte | ◆ Επικαλυμμένη πλάκα Pin |
| | ♦ Pinplate revestida | |
| | ◆ Tampone di lavaggio | ♦ Wash buffer |
| WASHB 50x | ◆ Tampon de Lavage | ♦ Solución de lavado |
| VW (011D 00X | ◆ Waschpuffer ◆ Solução do lavagom | ◆ Ρυθμιστικό διάλυμα πλύσης |
| | Solução de lavagem Tompana substrata | A Cubahata buffer |
| | ◆ Tampone substrato◆ Substrat | ◆ Substrate buffer◆ Tampón sustrato |
| SUB | ◆ Substrat ◆ Substratpuffer | ▼ ιαπιροπ sustrato ◆ Ρυθμιστικό διάλυμα υποστρώματος |
| 235 | ◆ Substrato | . I doplotiko otakopa ottootpupatos |
| | Reagente bloccante | ♦ Stop solution |
| OTOD | ◆ Solution d'Arrêt | ♦ Solución de parada |
| [S10P] | ♦ Stopreagenz | Αντιδραστήριο διακοπής αντίδρασης |
| | ♦ Solucão de paragem | |
| | ◆ Tampone campione | ♦ Sample buffer |
| | ◆ Tampon Echantillons | ◆ Tampón Muestras |
| OD E | • | • |
| SB 5x | ◆ Probenpuffer ◆ Diluente de amostra | ♦ Ρυθμιστικό διάλυμα δειγμάτων |